The similar result was observed for insulin glargine users versus human insulin users (OR 0.64 95% CI 0.60 to 0.68, P = 0.000; p for heterogeneity = 0.410, I2 = 0%). No significant difference was found in overall cancer for insulin glargine users versus insulin isophane users (OR 0.67, 95% CI 0.43 to 1.07, P = 0.091) in a random-effects model, with significant heterogeneity (P = 0.02, I2 = 81%). The gene discussed is INS; the disease is cancer.